Clinical Cancer Research Abstracts
Careers
Contact | Tell Us About Your Study
Oncology Expertise
Immunotherapy
Operational Expertise
Investigator Relationships
Site Training
Indications
Services
Oncology CRO Services
Study Design
Study Launch
Study Management
Medical Writing
B/DM
Study Rescue
Drug Development Consulting
Access to the U.S. Market
Bioequivalence Design
Experience
Trial Experience
Drug Therapies
Rescue Studies
About
Approach
History
Leadership
Partners
Therapeutic Areas
Oncology
Dental
Nephrology
Medical Device and Diagnostics
Neurology and CNS
News/Blog
Home
Oncology Expertise
Services
Experience
About
Therapeutic Areas
News/Blog
Abstracts
Careers
Contact
Phase I
News
Thought leaders
Phase I
Contract research
Drug development
Contract research
Phase I
Phase II
Speed to market
Thought leaders
Dan Von Hoff discusses “The Complete Phase Ib”
Medelis has published a free new downloadable abstract,…
Read Article
Cost containment
Electronic data capture
Phase I
EDC: Worth the investment in phase I trials?
This month, Clinpage is publishing a special report,…
Read Article
Phase I
Site Selection
In a phase I trial, how many sites is ideal?
In the last few posts we’ve been talking…
Read Article
Phase I
Site Selection
Evaluating a trial site’s track record
This month we've been writing about selecting sites…
Read Article
Phase I
Site Selection
Academic versus private sites
In our last post, we talked about the…
Read Article
Phase I
Site Selection
Clinical Trial Site Selection – The Importance of a Dedicated Team
Site selection is a key decision at the…
Read Article
Phase I
在美国拯救肿瘤学研究
当初创生物技术或制药公司在美国进行第一次实质性的 I/II 期、II 期或 III 期肿瘤学研究时,时间线通常会延长。 肿瘤学研究很复杂,即使是经验丰富的临床开发领导者也会因错过患者入组截止日期而受苦。随着新免疫疗法的发展,这种情况变得越来越普遍,这需要内部临床操作团队、站点以及所有 CRA…
Read Article
« First
«
1
2